{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:49:04Z","timestamp":1776426544535,"version":"3.51.2"},"reference-count":33,"publisher":"Elsevier BV","issue":"47-48","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.vaccine.2006.05.016","type":"journal-article","created":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T19:53:12Z","timestamp":1149191592000},"page":"6944-6954","source":"Crossref","is-referenced-by-count":18,"title":["Surrogate markers of immunity to Leishmania major in leishmanin skin test negative individuals from an endemic area re-visited"],"prefix":"10.1016","volume":"24","author":[{"given":"Susanne","family":"Nyl\u00e9n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Khamesipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Jafari-Shakib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liv","family":"Eidsmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sassan","family":"Noazin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farrokh","family":"Modabber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Akuffo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2006.05.016_bib1","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nri933","article-title":"The immunology of susceptibility and resistance to Leishmania major in mice","volume":"2","author":"Sacks","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2006.05.016_bib2","first-page":"377","article-title":"The effectiveness of leishmanisation in control of cutaneous leishmaniasis","volume":"76","author":"Nadim","year":"1983","journal-title":"Bull Soc Pathol Exot"},{"key":"10.1016\/j.vaccine.2006.05.016_bib3","first-page":"749","article-title":"Development of a storable Leishmania tropica vaccine: field testing with frozen promastigotes","volume":"47","author":"Witztum","year":"1979","journal-title":"Israel J Med Sci"},{"key":"10.1016\/j.vaccine.2006.05.016_bib4","first-page":"259","article-title":"The present and future vaccination for cutaneous leishmaniasis","volume":"47","author":"Greenblatt","year":"1980","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.vaccine.2006.05.016_bib5","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(98)09552-X","article-title":"Randomised vaccine trial of a single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam","volume":"351","author":"Sharifi","year":"1998","journal-title":"Iran Lancet"},{"key":"10.1016\/j.vaccine.2006.05.016_bib6","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(00)03128-7","article-title":"Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind. BCG-controlled trial in Sudan","volume":"356","author":"Khalil","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2006.05.016_bib7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/00034983.1985.11811917","article-title":"An experimental vaccine against American dermal leishmaniasis: experience in the State of Espirito Santo","volume":"79","author":"Mayrink","year":"1985","journal-title":"Brazil Ann Trop Med Parasitol"},{"key":"10.1016\/j.vaccine.2006.05.016_bib8","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/ije\/15.4.572","article-title":"Controlled field trials of a vaccine against New World cutaneous leishmaniasis","volume":"15","author":"Antunes","year":"1986","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2006.05.016_bib9","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(89)92686-X","article-title":"Effects of intradermal gamma-interferon in cutaneous leishmaniasis","volume":"1","author":"Harms","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2006.05.016_bib10","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1128\/IAI.68.4.1760-1764.2000","article-title":"Comparison of the immuneprofile of nonhealing cuteneous leishmaniasis patients with those with active lesions and those who have recovered from infection","volume":"68","author":"Adjary","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.05.016_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1365-2249.2003.02299.x","article-title":"Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG","volume":"134","author":"Mahmoodi","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2006.05.016_bib12","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1172\/JCI116372","article-title":"In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma [see comments]","volume":"91","author":"Karp","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2006.05.016_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/infdis\/175.3.737","article-title":"Leishmania aethiopica derived from diffuse leishmaniasis patients preferentially induce mRNA for IL-10 while those from localized leishmaniasis patients induce IFN\u03b3","volume":"175","author":"Akuffo","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.05.016_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0001-706X(01)00085-7","article-title":"Epidemiological study in a new focus of cutaneous leishmaniosis due to Leishmania major in Ardestan town, central Iran","volume":"79","author":"Yaghoobi-Ershadi","year":"2001","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2006.05.016_bib15","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/S0264-410X(01)00058-5","article-title":"Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG","volume":"19","author":"Misra","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.05.016_bib16","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0264-410X(02)00458-9","article-title":"The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis","volume":"21","author":"Alimohammadian","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.05.016_bib17","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1056\/NEJM197509042931013","article-title":"Editorial: measurement of delayed skin-test responses","volume":"293","author":"Sokal","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2006.05.016_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-3083.1992.tb01647.x","article-title":"Cells from healthy non-exposed individuals produce cytokines to selected fractions of Leishmania promastigotes","volume":"36","author":"Maasho","year":"1992","journal-title":"Scand J Immunol"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2006.05.016_bib19","first-page":"77","article-title":"Separation of lymphocytes from blood and bone marrow","volume":"21","author":"B\u00f8yum","year":"1969","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.vaccine.2006.05.016_bib20","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1016\/j.vaccine.2005.02.015","article-title":"Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis","volume":"23","author":"Khamesipour","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.05.016_bib21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0035-9203(02)90445-1","article-title":"The effect of repeated leishmanin skin testing on the immune responses to Leishmania antigen in healthy volunteers","volume":"96","author":"Satti","year":"2002","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2006.05.016_bib22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2249.2003.02096.x","article-title":"Live Leishmania promastigotes can directly activate primary human natural killer cells to produce inferferon-gamma","volume":"131","author":"Nyl\u00e9n","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2006.05.016_bib23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0035-9203(03)90171-4","article-title":"Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guerrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers","volume":"97","author":"Kamil","year":"2003","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2006.05.016_bib24","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4049\/jimmunol.136.7.2348","article-title":"Two types of murine helper T-cell clone. Part 1. Definition according to profiles of lymphokine activities and secreted proteins","volume":"136","author":"Mosmann","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2006.05.016_bib25","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1073\/pnas.88.16.7011","article-title":"Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis","volume":"88","author":"Heinzel","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2006.05.016_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2249.1999.00844.x","article-title":"Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia","volume":"116","author":"Sassi","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2006.05.016_bib27","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0264-410X(00)00401-1","article-title":"Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers","volume":"19","author":"Satti","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.05.016_bib28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1590\/S0074-02761998000200014","article-title":"Phase 1 study of an inactivated vaccine against American tegumentary leishmaniasis in normal volunteers in Brazil","volume":"93","author":"Marzochi","year":"1998","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.vaccine.2006.05.016_bib29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0738-081X(96)00072-7","article-title":"Stepwise safety trial of a killed Leishmania vaccine in Iran","volume":"14","author":"Dowlati","year":"1996","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.vaccine.2006.05.016_bib30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0738-081X(96)00071-5","article-title":"Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers","volume":"14","author":"Bahar","year":"1996","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.vaccine.2006.05.016_bib31","unstructured":"I. Satti, Immunogenicity of anti-leishmanial vaccines in man. Stockholm: MTC, Karolinska Institutet; 2004."},{"key":"10.1016\/j.vaccine.2006.05.016_bib32","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.vaccine.2003.06.002","article-title":"Safety, immunogenicity and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis","volume":"22","author":"Armijos","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.05.016_bib33","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0264-410X(98)00220-5","article-title":"A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran","volume":"17","author":"Momeni","year":"1999","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06005494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06005494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T15:57:07Z","timestamp":1683475027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06005494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":33,"journal-issue":{"issue":"47-48","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0264410X06005494"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.05.016","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}